Difference between revisions of "MSK Biomarker Ctte"

Revision as of 19:47, 29 June 2020

Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD

RSNA Staff Support: Susan Stanfa

The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.

Approved call summaries:

MSK Biomarker Committee Call Summaries Archive

QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease

Revision as of 15:29, 23 June 2020 (view source) SStanfa (talk \| contribs) (→‎Meetings) ← Older edit		Revision as of 19:47, 29 June 2020 (view source) SStanfa (talk \| contribs) Newer edit →
Line 5:		Line 5:

	The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.		The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
		+
		+
		+	:[[File:MSK_Profile-Wiki_Announcement-2.PNG\|700px\|link=Profiles]]